Affiliations: [a] Department of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China | [b] Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China | [c] Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China | [d] Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Correspondence:
[*]
Corresponding authors: Wei Zhu, Ping Liu, Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, China. Tel.: +86 25 83718836 6080; Fax: +86 25 83780826; E-mail:zhuwei1983213@163.com,liu-ping@csco.org.cn
Abstract:
BACKGROUND: MiR-4728 was recently identified to be related with
HER2 in several cell lines and limited tissue samples. OBJECTIVE: To investigate whether miR-4728 could predict HER2
status in a larger cohort. METHODS: The expression of miR-4728-3p and miR-4728-5p was
identified in breast cancer (BC) and gastric cancer (GC) tissues with
different HER2 status using quantitative reverse transcription polymerase
chain reaction (qRT-PCR) and fluorescence in situ hybridization (FISH). An
additional 22 plasma samples was investigated to explore the potential
application of miR-4728 as a non-invasive biomarker in predicting HER2
status. RESULTS: MiR-4728-3p and miR-4728-5p were significantly
up-regulated in HER2-positive patients compared with HER2-negative patients.
Compared with the expression in adjacent normal tissues, miR-4728-3p and
miR-4728-5p were both elevated in HER2-negative and HER2-positive GC tissues
but only miR-4728-3p in HER2-positive BC tissues. Further analyses revealed
that miR-4728-3p had greater ability than miR-4728-5p in discriminating
subgroups with different intensity of HER2 staining in both BC and GC
patients. In addition, miR-4728-3p but not miR-4728-5p was significantly
up-regulated in plasma of BC patients with positive HER2. CONCLUSIONS: MiR-4728-3p had better ability in distinguishing
patients with different status of HER2 than miR-4728-5p. And plasma
miR-4728-3p might act as a non-invasive biomarker in predicting HER2 status.
